Our meta-analysis concerned only the association between ABCB1 C3435T polymorphism and drug-resistant epilepsy, which revealed a significant risk to pharmacoresistance (OR = 1.877, 95% CI 1.213–2.905, P = 0.005) (Fig. 2). Here, ABCB1 is linked to epilepsy.